ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2)

Active
Institution
UNIVERSITY OF ILLINOIS AT CHICAGO, IL
Principal investigator
Sybil Hosek
Funding
$1.6M
Duration
2022–2027
Open portfolio

Moonbase score

Still being scored

Abstract

ABSTRACT Despite advances in HIV diagnostics, care and prevention strategies, HIV infection rates among adolescents and young adults in the United States (US) remain stubbornly high. There is an urgent need to describe the epidemiology and trajectories of HIV acquisition in this population and to offer age-appropriate, scalable prevention interventions to those at highest risk of infection in the US. This project will engage and retain sexually-active adolescents and young adults in the US in an innovative longitudinal cohort, enroll them in a dynamic established digital health retention platform (HMP; HealthMPowerment), monitor HIV risk and prevention behaviors and explore the socioecological factors that influence the use of new HIV prevention technologies (UG3 phase), while also allowing targeted testing of novel digital health interventions (UH3 phase). We will also test the efficacy of expanding the core version of HMP (HMP Basic) by adding adherence tools (HMP Enhanced) for those who are on PrEP or ART to improve adherence and persistence. In Aim 1, we will enroll and retain a large (n=3000) cohort of sexually active adolescents and young adults, ages 13-34, who are at risk for HIV using innovative digital recruitment, engagement and retention strategies. Over the course of the study, we will longitudinally characterize the sexual behavior, HIV transmission risk, and PrEP uptake trajectories of youth utilizing epidemiological trajectory analyses to identify the most effective points of intervention (Aim 2). For Aim 3, we will launch a randomized clinical trial to examine the efficacy of HMP Enhanced to improve PrEP adherence among HIV-negative youth (n ≥750) and ART adherence among HIV-positive youth (n ≥150) compared to HMP Basic. Finally, we will maximize the productivity of the cohort by testing new and innovative digital health devices, HIV/STI diagnostics and interventions, informed by the previous aims as well as emerging NIH prevention priorities (Aim 4). Our investigative team has decades of experience with recruitment, prevention and care of at-risk youth and large-scale longitudinal cohort studies. This study will capitalize upon productive existing partnerships and digital health expertise to articulate the drivers of the ongoing HIV epidemic among the most vulnerable populations in the US in order to identify the most effective, expeditious and scalable strategies to address this ongoing public health crisis.

Research team

  • Audrey FrenchPI
  • Lisa B Hightow-WeidmanPI
  • Sybil HosekPI

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUH3ZAI1-KSW-A(J1)digital healthyoung adultsadherenceyouthprepadolescents younghiv riskhiv

Questions for UNIVERSITY OF ILLINOIS AT CHICAGO

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.